CN107137701B - 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 - Google Patents
一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 Download PDFInfo
- Publication number
- CN107137701B CN107137701B CN201710314783.4A CN201710314783A CN107137701B CN 107137701 B CN107137701 B CN 107137701B CN 201710314783 A CN201710314783 A CN 201710314783A CN 107137701 B CN107137701 B CN 107137701B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- tumor
- inhibitor
- liver cancer
- socs2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 18
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 17
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 title abstract description 36
- 230000000694 effects Effects 0.000 title abstract description 17
- 229940029030 dendritic cell vaccine Drugs 0.000 title abstract description 12
- 229960005486 vaccine Drugs 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 title abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims abstract description 17
- 229940022399 cancer vaccine Drugs 0.000 claims abstract description 8
- 238000009566 cancer vaccine Methods 0.000 claims abstract description 8
- 230000014509 gene expression Effects 0.000 abstract description 20
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 12
- 108020004459 Small interfering RNA Proteins 0.000 abstract description 11
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 19
- 230000006807 siRNA silencing Effects 0.000 description 11
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 230000030279 gene silencing Effects 0.000 description 10
- 239000013642 negative control Substances 0.000 description 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000005760 tumorsuppression Effects 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102100022297 Integrin alpha-X Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 101150107526 Socs2 gene Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CGVWDTRDPLOMHZ-FXQIFTODSA-N Gln-Glu-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O CGVWDTRDPLOMHZ-FXQIFTODSA-N 0.000 description 1
- HLYCMRDRWGSTPZ-CIUDSAMLSA-N Glu-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CS)C(=O)O HLYCMRDRWGSTPZ-CIUDSAMLSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- INXAPZFIOVGHSV-CIUDSAMLSA-N Pro-Asn-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 INXAPZFIOVGHSV-CIUDSAMLSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
组别 | SOCS2 mRNA相对表达量 |
阴性对照组 | 1.24 |
siRNA沉默组 | 0.32 |
外源肽沉默组 | 0.39 |
组别 | 体内抑瘤率(%) |
阴性对照组 | 35 |
siRNA沉默组 | 73 |
外源肽沉默组 | 67 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710314783.4A CN107137701B (zh) | 2017-05-07 | 2017-05-07 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710314783.4A CN107137701B (zh) | 2017-05-07 | 2017-05-07 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107137701A CN107137701A (zh) | 2017-09-08 |
CN107137701B true CN107137701B (zh) | 2020-07-14 |
Family
ID=59778644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710314783.4A Active CN107137701B (zh) | 2017-05-07 | 2017-05-07 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107137701B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101437834A (zh) * | 2004-07-19 | 2009-05-20 | 贝勒医学院 | 细胞因子信号转导调节剂的调节和用于免疫治疗的应用 |
CN101501055A (zh) * | 2005-06-23 | 2009-08-05 | 贝勒医学院 | 负性免疫调节因子的调节和免疫疗法应用 |
CN101932339A (zh) * | 2007-11-30 | 2010-12-29 | 贝勒医学院 | 树突细胞疫苗组合物及其应用 |
WO2012156473A2 (en) * | 2011-05-16 | 2012-11-22 | University Of Tartu | A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit |
CN104508149A (zh) * | 2012-07-27 | 2015-04-08 | 诺华股份有限公司 | 对jak/stat抑制剂治疗响应的预测 |
CN105247371A (zh) * | 2013-06-17 | 2016-01-13 | 德国癌症研究公共权益基金会 | 通过转录因子tsc22d4的抑制剂治疗胰岛素抵抗 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012109476A2 (en) * | 2011-02-09 | 2012-08-16 | The University Of Rochester | Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements |
-
2017
- 2017-05-07 CN CN201710314783.4A patent/CN107137701B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101437834A (zh) * | 2004-07-19 | 2009-05-20 | 贝勒医学院 | 细胞因子信号转导调节剂的调节和用于免疫治疗的应用 |
CN101501055A (zh) * | 2005-06-23 | 2009-08-05 | 贝勒医学院 | 负性免疫调节因子的调节和免疫疗法应用 |
CN101932339A (zh) * | 2007-11-30 | 2010-12-29 | 贝勒医学院 | 树突细胞疫苗组合物及其应用 |
WO2012156473A2 (en) * | 2011-05-16 | 2012-11-22 | University Of Tartu | A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit |
CN104508149A (zh) * | 2012-07-27 | 2015-04-08 | 诺华股份有限公司 | 对jak/stat抑制剂治疗响应的预测 |
CN105247371A (zh) * | 2013-06-17 | 2016-01-13 | 德国癌症研究公共权益基金会 | 通过转录因子tsc22d4的抑制剂治疗胰岛素抵抗 |
Non-Patent Citations (4)
Title |
---|
"MULTISPECIES: DNA polymerase III subunit gamma/tau[Aerococcus],ACCESSION WP_070431481 ";Genbank;《Genbank》;20161027;第1页 * |
"SOCS-2和STAT-5在肝细胞癌组织中的表达及临床意义";师文楷;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20150215(第2期);第E072-621页 * |
"SOSC2 Influences LPS Induced Human Monocyte-Derived Dendritic Cell Maturation";Jin Hu et al.;《PLoS ONE》;20090925;第4卷(第9期);第1-8页 * |
"树突状细胞肿瘤疫苗研究进展";王莉等;《癌症进展杂志》;20050731;第3卷(第4期);第360-366,400页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107137701A (zh) | 2017-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102049928B1 (ko) | 효모-muc1 면역요법 조성물 및 그 용도 | |
EP3889253A1 (en) | Dendritic cell composition | |
Hon et al. | bcl-xL is critical for dendritic cell survival in vivo | |
KR20170054310A (ko) | 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법 | |
HUT73383A (en) | Process for preparing cancer vaccines | |
US11072802B2 (en) | Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product | |
JP2018203765A (ja) | 抗nme抗体 | |
JP7096639B2 (ja) | テロメラーゼ由来のペプチドを含む樹状細胞治療剤及び免疫治療剤、及びこれを用いる治療方法 | |
Kato et al. | RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6. 3 prostate cancer | |
CN110205335A (zh) | 以序列优化的分泌形式的FAPα为基础的肿瘤DNA疫苗的应用 | |
CN107137701B (zh) | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 | |
KR100647847B1 (ko) | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법 | |
CN107335054B (zh) | 一种慢性乙肝治疗性dc疫苗 | |
KR101173042B1 (ko) | 재조합 사이토카인 융합 단백질 및 이를 유효성분으로 하는종양 예방 또는 치료용 백신 보조제 | |
CN104450781A (zh) | 一种过表达ciapin1蛋白的细胞系及其制备方法和应用 | |
CN105585637B (zh) | 基于il-12稳定膜表达的肿瘤治疗剂及其制法和用途 | |
KR101711730B1 (ko) | Dab2 유전자가 과발현된 수지상 세포를 포함하는 자가면역질환 예방 또는 치료용 약제학적 조성물 | |
US7842782B2 (en) | Heparanase-derived peptides for vaccination of tumor patients | |
CN113461805B (zh) | 一种嵌入抗原表位肽的荧光素酶及其构建方法和应用 | |
US20130130990A1 (en) | Use of spink6 gene and its encoded protein for the preparation of an anti-tumor drug | |
CN114657158B (zh) | Ido1相关疫苗及其应用 | |
NL2031110B1 (en) | Recombinant adeno-associated virus vector, recombinant adeno-associated virus aav8-pd1 and use thereof | |
KR100647844B1 (ko) | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 효능을 분석하는 방법 | |
CN110156877B (zh) | 抑制肿瘤的多肽类似物UBE2Z1-330aa及其编码核酸、引物对、表达载体和应用 | |
Ning et al. | Construction of eukaryotic expression vector containing B7-1/GFP gene and its expression in osteosarcoma cell line |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200615 Address after: 261000 hi tech Industrial Development Zone, Weifang, Shandong, Gaomi City Applicant after: SHANDONG XINRUI BIOTECHNOLOGY Co.,Ltd. Address before: 211198 No. 18 Zhilan Road, Science Park, Jiangning District, Nanjing City, Jiangsu Province Applicant before: NANJING GAISIFU MEDICAL TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A gene target, inhibitor and DC tumor vaccine for improving the anti hepatoma effect of DC vaccine Effective date of registration: 20200917 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020980006170 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210914 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020980006170 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A gene target, inhibitor and DC tumor vaccine for improving the anti liver cancer effect of DC vaccine Effective date of registration: 20210915 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021370010092 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220905 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY CO.,LTD. Registration number: Y2021370010092 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A gene target, inhibitor and DC tumor vaccine to improve the effect of DC vaccine against liver cancer Effective date of registration: 20220906 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY CO.,LTD. Registration number: Y2022370010139 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |